Diagnosis and Management of Fetal Arrhythmias in the Current Era.

J Cardiovasc Dev Dis

Division of Cardiology, Departments of Pediatrics and Biomedical Engineering, Children's Wisconsin, Herma Heart Institute, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Published: May 2024

Diagnosis and management of fetal arrhythmias have changed over the past 40-50 years since propranolol was first used to treat fetal tachycardia in 1975 and when first attempts were made at in utero pacing for complete heart block in 1986. Ongoing clinical trials, including the FAST therapy trial for fetal tachycardia and the STOP-BLOQ trial for anti-Ro-mediated fetal heart block, are working to improve diagnosis and management of fetal arrhythmias for both mother and fetus. We are also learning more about how "silent arrhythmias", like long QT syndrome and other inherited channelopathies, may be identified by recognizing "subtle" abnormalities in fetal heart rate, and while echocardiography yet remains the primary tool for diagnosing fetal arrhythmias, research efforts continue to advance the clinical envelope for fetal electrocardiography and fetal magnetocardiography. Pharmacologic management of fetal arrhythmias remains one of the most successful achievements of fetal intervention. Patience, vigilance, and multidisciplinary collaboration are key to successful diagnosis and treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11204159PMC
http://dx.doi.org/10.3390/jcdd11060163DOI Listing

Publication Analysis

Top Keywords

fetal arrhythmias
20
management fetal
16
diagnosis management
12
fetal
12
fetal tachycardia
8
heart block
8
fetal heart
8
arrhythmias
5
diagnosis
4
arrhythmias current
4

Similar Publications

Advances and challenges of prenatal interventions for fetal tachyarrhythmias.

Front Pediatr

December 2024

Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

It is estimated that 1%-2% of pregnancies are complicated by fetal arrhythmias, with most arrhythmias considered benign and not requiring further treatment or intervention. However, persistent tachyarrhythmias can lead to fetal heart failure, preterm birth, stillbirth, and increased risks during the perinatal period. Therefore, timely treatment during pregnancy is often necessary.

View Article and Find Full Text PDF

Normal echocardiographic findings in healthy pregnant women: A narrative review of the literature.

Curr Probl Cardiol

December 2024

Cardiology Section, Internal Medicine Department, Universidad de Antioquia, Medellín, Colombia; Cardiopulmonary and Peripheral Vascular Service, Hospital San Vicente Fundación, Medellín, Colombia; Cardio-Obstetric Clinical Leader, Hospital San Vicente Fundación, Medellín, Colombia.

During pregnancy, significant physiological changes occur that result in cardiac remodeling and altered functional performance, though these are generally reversible postpartum. Pregnancy increases the cardiovascular system's demand, requiring substantial adaptations such as elevated cardiac output (CO), plasma volume, stroke volume (SV), and heart rate (HR), alongside a reduction in systemic vascular resistance (SVR) and mean arterial pressure. These adaptations, essential to meet the hemodynamic needs of both the mother and fetus, often differ from standard echocardiographic measurements used to evaluate cardiac function, making interpretation challenging.

View Article and Find Full Text PDF

Fetal bradycardia associated with left ventricle noncompaction diagnosed as HCN4 mutations.

Ann Pediatr Cardiol

November 2024

Department of Pediatric Cardiology, Nagano Children's Hospital, Nagano, Japan.

A 35-year-old pregnant woman was referred to our hospital because of fetal bradycardia. Fetal echocardiography revealed a normal fetal heart except for slightly prominent trabeculae in the left ventricle, normal cardiac function, and fetal sinus bradycardia with a heart rate of 100 bpm. Electrocardiography (ECG) after birth revealed sinus bradycardia with a heart rate of 70-80 bpm.

View Article and Find Full Text PDF

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic arrhythmic syndrome caused by mutations in the calcium (Ca) release channel ryanodine receptor (RyR2) and its accessory proteins. These mutations make the channel leaky, resulting in Ca-dependent arrhythmias. Besides arrhythmias, CPVT hearts typically lack structural cardiac remodeling, a characteristic often observed in other cardiac conditions (heart failure, prediabetes) also marked by RyR2 leak.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!